Related Experiment Video

Updated: Jul 4, 2026

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
09:33

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases

Published on: July 28, 2013

Histologically validated diffusion MRI signatures of neuroinflammation and neurodegeneration in Alzheimer disease

Qing Wang, Meng Jiang, Aime Luna

    Medrxiv : the Preprint Server for Health Sciences
    |July 3, 2026
    PubMed

    Insights

    Generalized diffusion basis spectrum imaging (g-DBSI) offers a new noninvasive MRI method to measure neuroinflammation in Alzheimer's disease. This technique shows promise as a biomarker for tracking disease progression and therapeutic development.

    Area of Science:

    • Neuroimaging
    • Alzheimer's Disease Research
    • Biomarker Development

    Background:

    • Noninvasive measurement of neuroinflammation is crucial for Alzheimer's disease (AD) therapeutics.
    • Current methods face challenges in specificity and regional consistency.

    Purpose of the Study:

    • To introduce generalized diffusion basis spectrum imaging (g-DBSI) as a novel diffusion MRI framework.
    • To validate g-DBSI metrics as noninvasive biomarkers for neuroinflammation and neurodegeneration in AD.

    Main Methods:

    • g-DBSI was applied to postmortem brains and 112 living participants stratified by amyloid PET.
    • Microstructural compartments (RIF, RAF) and their ratio (RIF/RAF) were analyzed.
    • Histopathology and CSF proteomics were used for validation.

    Main Results:

    • g-DBSI metrics (RIF, RAF, RIF/RAF) correlated with cellularity, neurofilament density, and amyloid-beta.
    • Amyloid-dependent trajectories in g-DBSI metrics were observed in living participants.
    • RIF/RAF linked to glia-enriched pathways, indicating neuroinflammation and neurodegeneration.

    Conclusions:

    • g-DBSI provides biologically interpretable MRI biomarkers for neuroinflammation in AD.
    • g-DBSI metrics demonstrate clinical compatibility and potential for tracking AD progression.
    • This framework supports the development of AD therapeutics by enabling noninvasive monitoring.

    More Related Videos

    Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-145105:17

    Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

    Published on: April 18, 2025

    Advanced Diffusion Imaging in The Hippocampus of Rats with Mild Traumatic Brain Injury10:33

    Advanced Diffusion Imaging in The Hippocampus of Rats with Mild Traumatic Brain Injury

    Published on: August 14, 2019

    Related Concept Videos

    Alzheimer Disease ll: Pathophysiology01:23

    Alzheimer Disease ll: Pathophysiology

    Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
    Alzheimer's Disease: Overview01:26

    Alzheimer's Disease: Overview

    Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
    The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
    Dementia l: Introduction01:22

    Dementia l: Introduction

    Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
    Alzheimer Disease l: Introduction01:29

    Alzheimer Disease l: Introduction

    Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...